Key result
Bleeding requiring exploration or chest tube placement occurred in 47% of pediatric patients on Berlin EXCOR VAD support, with no differences in coagulation parameters compared to non-bleeders.
Why the study?
Do abnormal coagulation parameters or antiplatelet agents increase bleeding requiring surgical intervention in pediatric patients on pulsatile ventricular assist device support?
Cohort (n=43)
Do abnormal coagulation parameters or antiplatelet agents increase bleeding requiring surgical intervention in pediatric patients on pulsatile ventricular assist device support?
Answers are grounded in this paper and cite their sources.
Bleeding requiring surgical intervention is common early after pediatric VAD implantation, but is not predicted by standard coagulation parameters or antiplatelet use.
Bleeding complications are a source of morbidity after Berlin EXCOR VAD implantation yet remain poorly characterized. We evaluated our experience to describe the bleeding complications among pediatric VAD recipients. We hypothesized that those with bleeding requiring exploration had abnormal coagulation profile compared with those without bleeding. The retrospective study included 43 consecutive patients with end-stage heart failure supported on pediatric mechanical cardiac support as a bridge to transplantation. Day-/event-based analysis on factors below associated with (i) bleeding and (ii) bleeding in next 48 h. Cases with bleeding were compared with day-matched patients without bleeding complications. Among 43 subjects bleeding occurred in 47% of cases, which necessitated exploration or chest tube placement. Twenty of 34 interventions for bleeding occurred in the first seven post-operative days. No differences in coagulation parameters or use of antiplatelet agents were noted among those who had bleeding vs. those who did not. Our results indicate that (i) re-bleeding requiring re-exploration was common, (ii) most of the bleeding occurred early post-implantation, (iii) there were no differences in coagulation parameters or the use of antiplatelet agents within 48 h of bleeding compared with those who did not bleed on each successive post-operative day.
No takes yet. Share an insight, caveat, or question.
Byrnes et al. (2014) conducted a cohort in end-stage heart failure (n=43). Berlin EXCOR VAD implantation was evaluated on Bleeding requiring exploration or chest tube placement. Bleeding requiring exploration or chest tube placement occurred in 47% of pediatric patients on Berlin EXCOR VAD support, with no differences in coagulation parameters compared to non-bleeders.
Synapse has enriched 10 related papers. Consider them for comparative context: